Lipidor AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIPI.ST research report →
Companylipidor.se
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
- CEO
- Ola Holmlund
- IPO
- 2019
- Employees
- 5
- HQ
- Danderyd, SE
Price Chart
Valuation
- Market Cap
- $174.88M
- P/E
- -6.74
- P/S
- 12491.56
- P/B
- 12.04
- EV/EBITDA
- -12.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -143150.00%
- Op Margin
- -101500.00%
- Net Margin
- -98614.29%
- ROE
- 1707.61%
- ROIC
- -184.02%
Growth & Income
- Revenue
- $14.00K · -82.05%
- Net Income
- $-13,806,000 · -20.21%
- EPS
- $-0.03 · 92.03%
- Op Income
- $-14,210,000
- FCF YoY
- 3.74%
Performance & Tape
- 52W High
- $0.50
- 52W Low
- $0.04
- 50D MA
- $0.25
- 200D MA
- $0.21
- Beta
- 0.68
- Avg Volume
- 7.63M
Get TickerSpark's AI analysis on LIPI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LIPI.ST Coverage
We haven't published any research on LIPI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIPI.ST Report →